- Home
- OTLK vs YSG Comparison
OTLK vs YSG Comparison
Compare OTLK & YSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | YSG |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 238.3M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OTLK | YSG |
|---|---|---|
| Price | $0.57 | $2.77 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.03 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 85.5K |
| Earning Date | 08-14-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | N/A | $4.74 |
| Revenue Next Year | $6,355.64 | $11.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $2.15 |
| 52 Week High | $2.54 | $9.06 |
Technical Indicators
Market Signals| Indicator | OTLK | YSG |
|---|---|---|
| Relative Strength Index (RSI) | 31.66 | 49.42 |
| Support Level | $0.50 | $2.64 |
| Resistance Level | $0.72 | $3.09 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.06 | 59.62 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.